The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Reversible BTK inhibitor nemtabrutinib (ARQ 531) for CLL and NHL
Nemtabrutinib (ARQ 531) is a reversible inhibitor of wild-type and C481S-mutant BTK. Here, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, tells us about the promising preliminary data from the Phase I dose escalation study (NCT03162536) across a variety of B-cell malignancies.
